🎉 M&A multiples are live!
Check it out!

Metagenomi Valuation Multiples

Discover revenue and EBITDA valuation multiples for Metagenomi and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Metagenomi Overview

About Metagenomi

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.


Founded

2016

HQ

United States of America
Employees

202

Website

metagenomi.co

Financials

LTM Revenue $47.2M

LTM EBITDA -$89.6M

EV

-$146M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Metagenomi Financials

Metagenomi has a last 12-month revenue of $47.2M and a last 12-month EBITDA of -$89.6M.

In the most recent fiscal year, Metagenomi achieved revenue of $52.3M and an EBITDA of -$83.5M.

Metagenomi expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Metagenomi valuation multiples based on analyst estimates

Metagenomi P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $44.8M $52.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$56.0M -$83.5M XXX XXX XXX
EBITDA Margin -125% -160% XXX XXX XXX
Net Profit -$43.6M -$68.3M XXX XXX XXX
Net Margin -97% -131% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Metagenomi Stock Performance

As of April 15, 2025, Metagenomi's stock price is $2.

Metagenomi has current market cap of $56.8M, and EV of -$146M.

See Metagenomi trading valuation data

Metagenomi Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$146M $56.8M XXX XXX XXX XXX $-2.37

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Metagenomi Valuation Multiples

As of April 15, 2025, Metagenomi has market cap of $56.8M and EV of -$146M.

Metagenomi's trades at -3.1x LTM EV/Revenue multiple, and 1.6x LTM EBITDA.

Analysts estimate Metagenomi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Metagenomi and 10K+ public comps

Metagenomi Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$146M XXX XXX XXX
EV/Revenue -2.8x XXX XXX XXX
EV/EBITDA 1.7x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Metagenomi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Metagenomi Valuation Multiples

Metagenomi's NTM/LTM revenue growth is -25%

Metagenomi's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Metagenomi's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Metagenomi's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Metagenomi and other 10K+ public comps

Metagenomi Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 17% XXX XXX XXX XXX
EBITDA Margin -160% XXX XXX XXX XXX
EBITDA Growth 49% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -185% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 61% XXX XXX XXX XXX
R&D Expenses to Revenue 209% XXX XXX XXX XXX
Opex to Revenue 270% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Metagenomi Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Metagenomi M&A and Investment Activity

Metagenomi acquired  XXX companies to date.

Last acquisition by Metagenomi was  XXXXXXXX, XXXXX XXXXX XXXXXX . Metagenomi acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Metagenomi

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Metagenomi

When was Metagenomi founded? Metagenomi was founded in 2016.
Where is Metagenomi headquartered? Metagenomi is headquartered in United States of America.
How many employees does Metagenomi have? As of today, Metagenomi has 202 employees.
Who is the CEO of Metagenomi? Metagenomi's CEO is Dr. Brian C. Thomas, PhD.
Is Metagenomi publicy listed? Yes, Metagenomi is a public company listed on NAS.
What is the stock symbol of Metagenomi? Metagenomi trades under MGX ticker.
When did Metagenomi go public? Metagenomi went public in 2024.
Who are competitors of Metagenomi? Similar companies to Metagenomi include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Metagenomi? Metagenomi's current market cap is $56.8M
What is the current revenue of Metagenomi? Metagenomi's last 12-month revenue is $47.2M.
What is the current EBITDA of Metagenomi? Metagenomi's last 12-month EBITDA is -$89.6M.
What is the current EV/Revenue multiple of Metagenomi? Current revenue multiple of Metagenomi is -3.1x.
What is the current EV/EBITDA multiple of Metagenomi? Current EBITDA multiple of Metagenomi is 1.6x.
What is the current revenue growth of Metagenomi? Metagenomi revenue growth between 2023 and 2024 was 17%.
Is Metagenomi profitable? Yes, Metagenomi is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.